NEWS
News
About
A company focused on new drug development for solid tumors.
An innovative therapeutic approach - MITTA (Minimally Invasive Targeted Tumor Ablation)
We are a human- and pet-focused drug discovery and development company with in-house R&D and manufacturing, pioneering new paths in cancer drug development and continuing to focus on "PTS (Para Toluenesulfonamide)" cancer drug development, as well as new drugs for various luminal tissue tumor therapies and other new drugs not yet marketed in the marketplace, with the goal of providing physicians and patients with effective, high-quality, and innovative medicines.
READ MORE
Cooperative institutes
121
facilities
Indications
22
types
R&D experience
24
years
Arrival countries
15+
Application category
Product 

Research and Development
Core Technology
Innovative Treatment Options: Minimally Invasive Targeted Tumor Ablation ApproachDrug/mechanical platform via image localization technology
Functional mechanism
PTS can selectively penetrate cancer cell membranes into the cytoplasm, and PTS causes lysosomal rupture in cancer cells: destroying the integrity of lysosomal membranes.
R&D Center
Our WuGu R&D Centers: Analytical Laboratory, SPF Pathogen Free Animal Room, BSL1 Cell Lab, BS .......
Journal publication
Our published papers
Cooperative institutes
Dr. Teng Small Animal Clinic
Tongji University Affiliated Shanghai Pulmonary Hospital
Shanghai General Hospital
TZUOO-ANN Animal Hospital
West China Hospital of Sichuan University
Dr. Teng Small Animal Clinic
Tongji University Affiliated Shanghai Pulmonary Hospital
Shanghai General Hospital
TZUOO-ANN Animal Hospital
West China Hospital of Sichuan University
Dr. Teng Small Animal Clinic
Tongji University Affiliated Shanghai Pulmonary Hospital
Shanghai General Hospital
TZUOO-ANN Animal Hospital
West China Hospital of Sichuan University